You are here

Thermo Fisher to buy Patheon for about $5.2 billion

May 15, 2017 (Reuters) – Thermo Fisher Scientific Inc , the world’s largest maker of scientific instruments, said on Monday it would buy contract manufacturing company Patheon NV for about $5.2 billion in cash. Thermo Fisher’s offer of $35 per share represents a premium of about 35 percent to Patheon’s Friday close. The deal represents a purchase price of about $7.2 billion, which includes the assumption of about $2.0 billion of net debt, the companies said in a statement. (Reporting by Ankur Banerjee in Bengaluru; Editing by Shounak Dasgupta) The…

Read More

Valeant swings to profit on tax gain, raises forecast

May 9, 2017 By Ankur Banerjee (Reuters) – Canada’s Valeant Pharmaceuticals International Inc reported its first profit in six quarters, helped by a one-time tax gain, and raised its full-year earnings forecast, sending its U.S. shares up 13 percent in premarket trading. Laval, Quebec-based Valeant has been trying to rebuild its business and regain investor confidence after the company came under investigations over its accounting and pricing practices. The company said it now expects 2017 adjusted earnings before interest, tax, depreciation and amortization (EBITDA) of $3.60-$3.75 billion, up from its…

Read More

Eli Lilly’s profit beats on demand for new drugs

April 25, 2017 By Ankur Banerjee (Reuters) – Eli Lilly and Co reported a bigger-than-expected quarterly adjusted profit as sales of its newest products, including a diabetes injection, more than doubled. The Indianapolis-based drugmaker reported strong first-quarter demand for its Trulicity diabetes treatment and its psoriasis drug, Taltz, as well as its Cyramza lung cancer treatment. “Lilly’s new product launches, including Trulicity and Taltz, led the company to a strong quarter of volume-driven revenue growth,” David Ricks, who took over as chief executive on Jan. 1, said in a statement….

Read More
Facebook Auto Publish Powered By :